Coherus Oncology (CHRS) Return on Capital Employed (2014 - 2026)
Coherus Oncology (CHRS) posted Return on Capital Employed of 132.34% for Q1 2026, down 80.5% sequentially from 73.32% in Q4 2025, and down 1778.0% YoY from 7.89% in Q1 2025.
Coherus Oncology (CHRS) Return on Capital Employed (2014 - 2026) Analysis & Trends
Coherus Oncology has reported Return on Capital Employed for 13 years, with the latest figure at 132.34% in Q1 2026.
- Quarterly Return on Capital Employed fell 1778.0% year-over-year to 132.34% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 132.34% (down 1778.0% YoY) and the FY2025 annual result came in at 85.02%, down 706.0% from the prior year.
- Return on Capital Employed declined to 132.34% in Q1 2026 per CHRS's latest filing, from 73.32% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 36.76% in Q1 2022 and troughed at 170.91% in Q3 2025.
- A 5-year average of 89.88% and a median of 76.58% in 2023 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 2971 bps in 2025, down 9509 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 68.1% in 2022, then dropped by 9 bps to 73.91% in 2023, then plunged by 39 bps to 103.03% in 2024, then rose by 29 bps to 73.32% in 2025, then plunged by 81 bps to 132.34% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 132.34%, 73.32%, and 170.91% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | -103.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -103.66% |
| Mar 31, 2026 | -132.34% |
| Dec 31, 2025 | -73.32% |
| Sep 30, 2025 | -170.91% |
| Jun 30, 2025 | -129.32% |
| Mar 31, 2025 | -114.57% |
| Dec 31, 2024 | -103.03% |
| Sep 30, 2024 | -75.82% |
| Jun 30, 2024 | -81.31% |
| Mar 31, 2024 | -128.41% |
| Dec 31, 2023 | -73.91% |
| Sep 30, 2023 | -64.73% |
| Jun 30, 2023 | -87.87% |
| Mar 31, 2023 | -76.58% |
| Dec 31, 2022 | -68.10% |
| Sep 30, 2022 | -64.95% |
| Jun 30, 2022 | -45.99% |
| Mar 31, 2022 | -36.76% |
| Dec 31, 2021 | -48.40% |
| Sep 30, 2021 | -49.46% |